Ipa library 2.0 virus10/29/2023 ![]() ![]() Results of the screening also indicate that identified antibodies retain the ability to bind to emerging SARS-CoV-2 variants including U.K. ![]() ![]() Twenty-seven extensively characterized, proprietary, lead candidate antibodies have been generated and analyzed by ImmunoPrecise in its preclinical studies to reveal full interaction profiles against seventeen different SARS-CoV-2 variants. (the "Company" or "IPA") (NASDAQ: IPA) (TSX VENTURE: IPA) a leader in full-service, therapeutic antibody discovery and development, today has confirmed the results of an additional PolyTope™ antibody interaction analysis against SARS-CoV-2 spike protein variants of concern. VICTORIA, British Columbia-( BUSINESS WIRE)-IMMUNOPRECISE ANTIBODIES LTD.
0 Comments
Leave a Reply.AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |